DXB

0.00%

37.5¢ dimerix limited

Ann: Gold Coast Investment Showcase Presentation, page-41

First 41 Last

Share
Profile

Follow
oilandgasman

1,344 Posts.

102

23/06/17

23:14

Post #: 25465020
Share

Originally posted by Ahmed ↑

Boccione,

Good post. However, it's important to clarify what negative results would look like.. In my opinion, a negative result would be where either one of the following two situations occurred:

1. There was a significant safety issue

Or

2. The proportion of patients with a 50% or greater reduction from baseline was much lower than seen after the interim results. I would say half the rate seen from interim- so 15% of lower of patients with this reduction would be negative IMO.

What is the likelihood of either of these situations..

1. If there was a very significant safety issue - then an announcement may have to have been made. Or if S were not that significant, then we will find out at results release. However, given this is a combination of two known and marketed drugs- the change is exceptionally low. Further to this- the interim results 11/27 patients had no safety issues. So - I'll bet my house this doesn't eventuate.

2. We received an update from the company stating that the ongoing results were in line with the interim results. This suggests that they have seen additional patients with a 50% or more reduction.. This is very positive and is why I believe the final results will confirm the great results seen at the interim release.

Once they characterise which patients have the best response to the drug combination and identify which dose(s) are most effective- they will certainly have something that big pharma would be very interested in.

Amazing opportunity to buy into this company at a sub $20M market cap. Look at PYC- near $100M market cap and have nothing compared to DXB. The receptor HIT platform will generate more lead combinations. I can see this going to $100M market cap too.. When. Not sure. But a licensing deal post results and we'll get there in a jiffy!

Expand

Agreed @Ahmed

I'm getting a little more than excited.

To take a critical stance for a moment: In regard to Receptor-HIT - the company must monetise or sell the platform. From what I've gathered, there have been a few companies who have had access to the platform so far and the benefit to Dimerix is not transparent or fully known to the market. In my opinion this has to be locked down and the market should be fully aware of all transactions and back room agreements and what they mean for future IP, revenue, etc.

Last edited by oilandgasman: 23/06/17

DXB Price at posting: 0.9¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

TYX

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

There are more pages in this discussion • 59 more messages in this thread...

First 41 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 37.5¢		Change 0.000(0.00%)		Mkt cap ! $209.1M

Open	High	Low	Value	Volume
38.0¢	38.5¢	36.5¢	$579.4K	1.548M

Buyers (Bids)

No.	Vol.	Price($)
1	91570	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
37.5¢	7922	2

View Market Depth

No.	Vol.	Price($)
1	91570	0.370
10	171185	0.365
13	301942	0.360
3	73000	0.355
9	211495	0.350

Price($)	Vol.	No.
0.375	7922	2
0.380	72644	5
0.390	17637	3
0.395	142800	4
0.400	277640	8

Last trade - 16.10pm 15/11/2024 (20 minute delay)

DXB (ASX) Chart

Ann: Gold Coast Investment Showcase Presentation, page-41

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Banshee's historic trenches prove rich in antimony and gold for GDM

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Gold Coast Investment Showcase Presentation, page-41

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Banshee's historic trenches prove rich in antimony and gold for GDM

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News